Location: Seattle, Washington, United States
Job Category: Technical Development
Work Location: 400 Dexter Ave N. 98109
Organization: Bioengineering
Employee Status: Full-time
Job Type: Regular
Juno Therapeutics, a Celgene company, is developing clinical-stage, novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer.
The Delivery Technologies group is seeking an enthusiastic, self-driven Senior Research Associate to join an innovation-focused, interdisciplinary team to contribute to technology development efforts focused on the implementation of a closed-system, manufacturing scale, formulation platform for non-viral gene delivery in CAR and TCR based cell therapies. This individual will work closely with a cross-functional team to develop screening methods to test non-viral formulations for nucleic acid transfection in primary T cells and to make improvements to non-viral constructs to enhance genomic integration via non-viral delivery technologies.
Primary Responsibilities
- Collaborate with Research, Analytical and Process Development, internal and external partners to develop a manufacturing scale, formulation platform for delivery of nucleic acids and proteins to primary T cells
- Participate on a cross-functional team tasked with integration of non-viral gene delivery into the T cell manufacturing process
- Generate material to support experiments (nucleic acids, protein-nucleic acid complexes and necessary reagents)
- Make improvements to construct design using molecular biology techniques to enhance genomic integration via non-viral delivery technologies
- Develop, execute, and troubleshoot experiments for the development of a robust, scalable gene delivery and editing platform (viral vector and non-viral) for T cells
- Maintain accurate and detailed laboratory notebook and documentation of experimental results
- Author technical reports and standard operating procedures (SOPs)
Basic Qualifications
- B.S. in Bioengineering, Chemical Engineering, Virology, Biology, Biochemistry, or related discipline, M.S. preferred
- 0-2 years (w/M.S.) 2-4 (w/B.S.) of industry experience in cell culture
- Strong background in molecular biology techniques, such as construct design, DNA/RNA amplification and analysis, and gene cloning
- Independently motivated to accomplish given tasks and work in teams
- Ability to communicate clearly and concisely through oral presentations and technical writing
- Strong organization, documentation, time management, and problem-solving skills with attention-to-detail
Preferred Qualifications
- Proficiency in molecular and cell biology techniques including PCR, restriction enzyme digests, Gibson and traditional cloning, vector/gene design, DNA sequencing, and qPCR
- Knowledge of genome editing technologies, gRNA design and verification
- Hands-on mammalian cell culture experience, experience w/ human primary T cells is a plus
- Experience with BD Flow Cytometer instrumentation (FACSCanto, Fortessa, Symphony, Aria, etc.)
- Working knowledge of flow cytometry analysis software (FlowJo, FACSDiva, FCSExpress, etc.) as well as statistical software (JMP, R, Spotfire, Prism, etc.)
- Ability to work collaboratively in a cross-functional scientific environment
- Understanding the rationale and scientific backgrounds of the projects and experiments
About Us
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
"At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients."
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.